Mohsen Zahiri1, Kevin M Chen1, He Zhou1, Hung Nguyen1, Biruh T Workeneh2, Sarvari V Yellapragada3, Yvonne H Sada3, Michael Schwenk4, Bijan Najafi5. 1. Interdisciplinary Consortium on Advanced Motion Performance (iCAMP), Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA. 2. Department of Nephrology, Division of Internal Medicine, MD Anderson, Houston, TX, USA. 3. Department of Medicine, Section of Hematology and Oncology, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Hematology and Oncology, Michael E. DeBakey VA Medical Center, Houston, TX, USA. 4. Network Aging Research (NAR), Heidelberg University, Heidelberg, Germany; Department of Sports and Sports Sciences, Heidelberg University, Heidelberg, Germany. 5. Interdisciplinary Consortium on Advanced Motion Performance (iCAMP), Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA. Electronic address: bijan.najafi@bcm.edu.
Abstract
OBJECTIVE: An essential component for optimizing quality of life in adults with cancer is determining the degree to which therapy may negatively impact motor-performance, so that patients can maintain their quality of life and independence. This study examined whether instrumented gait and balance could determine the magnitude of deterioration in motor-performance from chemotherapy-induced peripheral neuropathy (CIPN). METHODS: We recruited 84 adults with cancer (age = 71.1 ± 9.7 years old, BMI = 26.8 ± 6.2 kg/m2, gender = 56%female) and 57 age-matched non-cancer patients (age = 69.5 ± 9.8 years old, BMI = 27.1 ± 6.0 kg/m2, gender = 79%female). Based on clinical screening, the group with cancer was classified into two groups: participants with CIPN (CIPN+) and without CIPN (CIPN-). Gait and balance were quantified using validated wearables. The Vibration Perception Threshold (VPT) test was used to stratify the CIPN+ group into mild (Mild-CIPN) and severe (Severe-CIPN) subgroups. RESULTS: All gait and balance parameters were deteriorated in the group with cancer compared to non-cancer group with the largest effects observed for stride-time (11%, Cohen's effect size d = 1.00, p < 0.001) and eyes-closed ankle sway (94%, d = 0.49, p = 0.001). The same trend was observed when the Severe-CIPN subgroup was compared to the Mild-CIPN. VPT correlates significantly with motor deterioration, with the largest correlation found in stride-time (Rho = 0.37, p = 0.007). Severe-CIPN subjects were significantly older and overall had more deterioration in the majority of motor-performance parameters after adjusting for age (p < 0.050). CONCLUSION: These results confirmed the negative impact of CIPN on motor-performance with the largest effects on ankle stability and stride-time. VPT is a predictor of motor deterioration and may be used to determine the severity of CIPN symptom.
OBJECTIVE: An essential component for optimizing quality of life in adults with cancer is determining the degree to which therapy may negatively impact motor-performance, so that patients can maintain their quality of life and independence. This study examined whether instrumented gait and balance could determine the magnitude of deterioration in motor-performance from chemotherapy-induced peripheral neuropathy (CIPN). METHODS: We recruited 84 adults with cancer (age = 71.1 ± 9.7 years old, BMI = 26.8 ± 6.2 kg/m2, gender = 56%female) and 57 age-matched non-cancerpatients (age = 69.5 ± 9.8 years old, BMI = 27.1 ± 6.0 kg/m2, gender = 79%female). Based on clinical screening, the group with cancer was classified into two groups: participants with CIPN (CIPN+) and without CIPN (CIPN-). Gait and balance were quantified using validated wearables. The Vibration Perception Threshold (VPT) test was used to stratify the CIPN+ group into mild (Mild-CIPN) and severe (Severe-CIPN) subgroups. RESULTS: All gait and balance parameters were deteriorated in the group with cancer compared to non-cancer group with the largest effects observed for stride-time (11%, Cohen's effect size d = 1.00, p < 0.001) and eyes-closed ankle sway (94%, d = 0.49, p = 0.001). The same trend was observed when the Severe-CIPN subgroup was compared to the Mild-CIPN. VPT correlates significantly with motor deterioration, with the largest correlation found in stride-time (Rho = 0.37, p = 0.007). Severe-CIPN subjects were significantly older and overall had more deterioration in the majority of motor-performance parameters after adjusting for age (p < 0.050). CONCLUSION: These results confirmed the negative impact of CIPN on motor-performance with the largest effects on ankle stability and stride-time. VPT is a predictor of motor deterioration and may be used to determine the severity of CIPN symptom.
Authors: Carol Sweeney; Kathryn H Schmitz; DeAnn Lazovich; Beth A Virnig; Robert B Wallace; Aaron R Folsom Journal: J Natl Cancer Inst Date: 2006-04-19 Impact factor: 13.506
Authors: Marta Seretny; Gillian L Currie; Emily S Sena; Sabrina Ramnarine; Robin Grant; Malcolm R MacLeod; Leslie A Colvin; Marie Fallon Journal: Pain Date: 2014-09-23 Impact factor: 6.961
Authors: Morag E Taylor; Kim Delbaere; A Stefanie Mikolaizak; Stephen R Lord; Jacqueline C T Close Journal: Gait Posture Date: 2012-07-23 Impact factor: 2.840
Authors: Susanna B Park; David Goldstein; Arun V Krishnan; Cindy S-Y Lin; Michael L Friedlander; James Cassidy; Martin Koltzenburg; Matthew C Kiernan Journal: CA Cancer J Clin Date: 2013 Nov-Dec Impact factor: 508.702
Authors: He Zhou; Hung Nguyen; Ana Enriquez; Louie Morsy; Michael Curtis; Timothy Piser; Christopher Kenney; Christopher D Stephen; Anoopum S Gupta; Jeremy D Schmahmann; Ashkan Vaziri Journal: Neurol Sci Date: 2021-10-19 Impact factor: 3.307
Authors: He Zhou; Catherine Park; Mohammad Shahbazi; Michele K York; Mark E Kunik; Aanand D Naik; Bijan Najafi Journal: Gerontology Date: 2021-05-10 Impact factor: 5.597